Abstract | The immune system evolved to distinguish non-self from self to protect the organism. As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge. This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumour microenvironment. The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed. Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy. Recent clinical trials using T cells engineered to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) have produced stunning results in patients with relapsed or refractory haematological malignancies. In this Review we describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail.
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; however, inherent to a persistent cancer is the ability to overcome such immune control. Since Medawar and colleagues 2 carried out their seminal work, it has long been recognized that adoptively transferred T cells have the potential to target and destroy cancer cells. In some cases, however, transferred T cells lacked sufficient specificity or numbers to completely reject a tumour [3] [4] [5] . T cells genetically engineered to express novel receptors have enhanced tumour specificity. In addition, advances in ex vivo expansion enable the production of clinically relevant doses of these therapeutic cells. Engineered T cells have produced unprecedented results in the clinic.
The earliest clinical trials of engineered T cells in cancer relied on the expression of cloned TCRs with targeted affinity for tumour antigens. A TCR may recognize either intracellular or extracellular antigen in the context of major histocompatibility complex (MHC) presentation. When designing a TCR to target tumour cells, having the option to target intracellular tumour antigen may be advantageous as this may expand the pool of potential targets. Conversely, many tumours down regulate MHC class I expression, potentially masking their presence from a TCR-engineered T cell 6 . More recently, artificial receptors, such as chimeric antigen receptors (CARs), have been used to enhance engineered T cell specificity (FIG. 2) .
Unlike TCRs, CARs enable highly specific targeting of antigen in an MHC-independent fashion. CARs are formed from a combination of antibody-derived or ligandderived domains and TCR domains. A CAR is commonly composed of a specificity-conferring, B cell receptor (BCR)-derived, extracellular antibody single-chain variable fragment (scFv), a TCR-derived CD3ζ domain and one or more intracellular co-stimulatory domains. CAR design has evolved over the years to enhance efficacy and safety in particular immunological settings (FIG. 3) . Until recently, however, CAR T cell targets were limited to extracellular tumour antigens.
Adoptive transfer of T cells expressing engineered receptors has shown enormous promise in humans. Adoptive transfer of CD19-directed CAR T (CART19) cells has generated complete and durable remissions in patients with refractory and relapsed B cell malignancies [7] [8] [9] [10] . NY-ESO-1 (also known as CTAG1A)-specific TCR-engineered T cells have generated clinical responses in patients with advanced multiple myeloma and synovial cell sarcoma 11, 12 . With the proof of concept established, engineered T cells have matured as a potential therapeutic option to treat malignancies. Building on this foundation, the field is broadening indications for current therapies, exploring new targets and using new techniques to create even safer and more effective therapies. In this Review, we describe some of the most recent and promising advances in engineered T cell therapy, with a particular emphasis on what the next generation of T cell therapy is likely to entail.
Clinical trials in B cell malignancies B cell malignancies are the most common tumour type to be targeted by engineered T cells. There are several reasons for this. B cell malignancies are relatively common and express several conserved cell surface markers. Acquired B cell aplasia is a treatable condition with mild to moderate long-term consequences. Circulating B cell tumours provide easy access for intravenously infused engineered T cells, reducing the requirement for therapeutic cells to traffic to the site of the tumour. Finally, the use of engineered T cells to treat B cell tumours, specifically B cell acute lymphoblastic leukaemia (B-ALL) has shown the greatest promise in the field to date.
The extracellular glycoprotein CD19 is the most common B cell target for engineered T cell therapies (TABLE 1) . CD19 is expressed on both benign and most malignant B cells, with extremely limited non-B cell expression 13 . Several groups have reported response rates to CART19 cells in more than 80% of patients with relapsed and refractory B-ALL [7] [8] [9] [10] . Moreover, several clinical tr ials have confirmed that CART19 cells are effective for treating refractory lymphoma with overall response rates of 50-80% 14, 15 . Others have targeted rare CD19 + multiple myeloma stem cells, demonstrating disease eradication at 12 months after adoptive transfer of CART19 cells 16 . Although further study is needed, engineered T cells have been shown to persist in at least one patient for more than a decade after transfer 17 , suggesting that adoptively transferred T cells may be truly a living drug.
Although CD19 is frequently expressed initially, it may be downregulated 18 or mutated 19 in tumour cells, enabling these cells to acquire resistance to CD19-directed therapy. Relapse rates in B-ALL reported at the 2015 American Society of Hematology meeting ranged from 18% to 36%, with most of these (66-100%) due to CD19 − relapses [20] [21] [22] [23] [24] . Alternative markers, such as CD20 and CD22, are also frequently expressed in non-Hodgkin lymphoma 25 and B-ALL 26 . Tolerability of CD20 monoclonal antibodies (rituximab) supports the safe use of anti-CD20 T cells. Although shown to be safe, autologous CD20-targeted CAR T (CART20) cells failed to persist in vivo in early trials, with loss of detectable modified cells occurring at between 1 and 9 weeks after transfer 27 . Inclusion of dual co-stimulatory domains (CD28 and 4-1BB (also known as TNFRSF9)) enhanced the persistence of CART20 cells in patients with indolent B cell lymphoma or mantle cell lymphoma 28 . These CART20 cells could be detected up to 1 year after transfer and two of the three patients treated had progression-free survival at 24-month follow-up. Preclinical data have demonstrated CD22-directed CAR T cell antitumour capacity 26 similar to that of CART20. Multiple phase I clinical trials using CART22 products are under way (TABLE 1) . Relapse after single-target engineered T cell therapy suggests either the selection of a previously undetectable target-negative clone or acquired resistance by the tumour cells. Combination therapy, simultaneously targeting two tumour markers, may prevent such escape.
During B cell development, a given cell will express either immunoglobulin-κ (Igκ) or Igλ light chains. In humans, the ratio of Igκ + to Igλ + cells ranges from 4:1 to 0.5:1. When the ratio exceeds these limits, it is likely that a clonal, Ig light chain-restricted population has expanded. Ig light chain targeting by CAR T cells is a particularly attractive approach because, unlike CD19, Ig light chain-targeted CAR T cells have the potential to leave 20-80% of B cells and plasma cells untouched. In addition, Igκ light chain immunodeficiency does not confer increased risk of infection 29 . Igκ-targeted CAR T cells have been shown to generate specific cytotoxicity in response to Igκ + tumour cell lines 30 . These cells are now in use as part of a phase I clinical trial to investigate safety and efficacy in humans (TABLE 1) .
Engineered T cells designed to target B cell malignancies serve as proof of concept that ex vivo modified T cells can eradicate tumour in humans (FIG. 4) . These engineered T cells have shown the ability to serially kill malignant B cells, suggesting that transfer of very few cells may be sufficient to achieve remission 31, 32 . Experience in manufacturing engineered T cells and Nature Reviews | Cancer Endogenous T cell receptors (TCRs) include paired α and β chains associated with δ, ε and γ chains, and signalling ζ chains. The antigen seen by the TCR is presented by either major histocompatibility complex (MHC) class I or MHC class II (class II shown). The specificity signal delivered through the TCR is commonly referred to as signal 1, as for complete activation leading to effector function, T cells require a co-stimulatory signal, referred to as signal 2. The most common activating co-stimulatory receptor domains that have been investigated in chimeric antigen receptor design are shown. If signal 1 can be thought of as the recognition signal, then signal 2 may be thought of as the on/off switch. The most prominent inhibitory co-stimulatory receptors are cytotoxic T lymphocyteassociated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1). CD28 and CTLA4 both bind to ligands CD80 and CD86, with relative expression determining the course of activation and inhibition of T cells. Many tumours upregulate PD1 ligand (PDL1 or PDL2), among other inhibitory ligands not shown, to turn off T cells. Tumours may also downregulate MHC to evade an effective immune response. ICOS, inducible T cell co-stimulator; LAT, linker for activation of T cell family member 1; ZAP70, ζ-associated protein of 70 kDa.
Cytokine release syndrome (CRS) . A serious and in some cases potentially life-threatening toxicity that has been observed after administration of natural and bispecific antibodies and, more recently, following adoptive T cell therapies for cancer. CRS is associated with elevated circulating levels of several cytokines including interleukin-6 (IL-6) and interferon-γ (IFNγ).
clinically managing recipients of those cells has been instructive and challenging. Patient-to-patient differences in the T cells collected for ex vivo engineering inevitably led to variation between lots, despite refinements to standardize the manufacturing process. One strategy to reduce variability may be to initiate cell manufacturing with a purer starting T cell population, by enriching for central memory T cells, or to set the ratio of CD4 + to CD8 + T cells in the engineered product at 1:1 (REFS 33, 34) . Clinical management of recipients of engineered T cells with rapid tumour clearance following infusion of redirected T cells has been complicated by the associated immune activation and cytokine release syndrome (CRS). To control such responses, careful management of patients with high tumour burden, including the use of anti-cytokine therapies, and development approaches to adjust T cell activity in vivo are under active investigation. Efficacy in treating different lymphoma histologies and the different response rates compared with ALL suggest that specific disease factors may need to be considered to enhance potency. Ultimately, the successful eradication of B cell malignancies by engineered T cells has provided the foundation on which the field of adoptive T cell therapy is expanding.
Moving beyond B cell malignancies Novel target selection for non-B cell haematological malignancies. Several targets in non-B cell malignancies are under investigation (TABLE 1) . Upon terminal differentiation, plasma cells downregulate many common engineered T cell targets such as CD19, CD20, CD22 and surface Ig light chains. Therefore, to effectively target malignant plasma cells in conditions such as multiple myeloma, new targets must be considered. One such target, B cell maturation antigen (BCMA; also known as TNFRSF17), is analogous to CD19 in that it is expressed in most cases of multiple myeloma and is not expressed on non-plasma cells 35, 36 . Unlike CD19, however, BCMA signalling can induce plasma cell proliferation and survival [37] [38] [39] [40] . Therefore, downregulation of BCMA by multiple myeloma cells to escape engineered T cell detection could limit tumour progression. BCMA-CAR T cells eradicate human multiple myeloma cell lines in xenograft models 41 . Two phase I trials are currently investigating the feasibility, safety and efficacy of BCMA-CAR T cells against multiple myeloma (TABLE 1) . Cancer-testis antigens, such as NY-ESO-1, are also upregulated on plasma cell myeloma cells and can be highly immunogenic 42 . T cells engineered to express an affinity-enhanced, NY-ESO-1-specific TCR have been used to treat patients with advanced multiple myeloma. Clinical responses in 16 of 20 patients with advanced disease were observed, suggesting great promise in an otherwise incurable disease 11 . Treatment of myeloid malignancies has not progressed substantially over past decades; however, engineered T cell therapy may change this. Myeloid cell surface markers upregulated on malignant cells (for example, CD33, CD123 (also known as IL3Rα) and CD44v6) are under investigation as T cell therapy targets [43] [44] [45] . Importantly, CD33 and CD123 are expressed on normal haematopoietic stem cells. Therefore, targeting these markers risks ablation of the haematopoietic stem cell compartment, which would be an intolerable on-target, off-tumour effect. Although preclinical animal studies are equivocal on the question of in vivo myeloablation 44, [46] [47] [48] , some have proposed combining anti-myeloid T cell therapy with subsequent bone marrow transplant as salvage therapy 44 . A phase I clinical trial is investigating the use of CD123-targeted CAR T cells in treating myeloid malignancies (TABLE 1) .
Interestingly, some potential haematological targets are not unique to haematological malignancy. For example, receptor tyrosine kinase-like orphan receptor (ROR1) is a transmembrane glycoprotein expressed on embryonal tissue and aberrantly on many adult malignant tissues 49, 50 . Aberrant cell surface expression of ROR1 has been described in chronic lymphocytic leukaemia (CLL), mantle cell lymphoma, B-ALL and numerous types of solid tumour [49] [50] [51] [52] . ROR1 expression seems to enhance cell survival and prevention of apoptosis, suggesting that downregulation of ROR1 may confer a proliferative disadvantage on tumour cells and may therefore be an unlikely mechanism of acquired resistance to ROR1-targeted engineered T cells 53, 54 . ROR1-targeted T cells generate cytotoxicity against human ROR1 + Nature Reviews | Cancer B cell malignancies and sarcoma in preclinical studies 52, 55, 56 . Importantly, despite low-level ROR1 expression in non-tumour tissue, transfer of ROR1-CAR T cells into non-human primates did not cause overt toxicity 57 . Autologous ROR1-directed CAR T cells are currently being investigated for safety and feasibility in a phase I trial to treat patients with CLL 58 (TABLE 1).
In search of specific solid tumour targets. Monoclonal antibodies directed against solid tumour antigens have shown promise in early clinical trials, although limited tissue penetration has restricted clinical responses 59 . Endogenous tumour-infiltrating lymphocytes (TILs) have long been known to generate antitumour immune responses and confer a positive prognosis; however, tumour immunosuppression prevents tumour clearance [60] [61] [62] . Given the ability of modified T cells to actively traffic to nearly every site in the body 63, 64 and to overcome tumour immune evasion 65 , engineered T cells possess unique potential to eliminate solid tumours. However, selecting appropriate solid tumour targets can be challenging. Most potential solid tumour targets are non-specific, being expressed on healthy tissue as well. At the same time, off-tumour effects may be less tolerable than the B cell aplasia associated with haematological CAR T cell therapies. Different levels of cell surface marker expression may enable engineered T cells to preferentially target malignant cells 56, 66, 67 ; however, low-level expression on healthy tissue inherently increases the risk of on-target, offtumour adverse effects. Those solid tumour targets that are highly specific for tumour tissue such as epidermal growth factor receptor variant III (EGFRvIII) may not be expressed throughout the tumour 68 . T cell therapy directed against a tumour target that is not present on all tumour cells runs the risk of selecting for targetnegative tumour outgrowth. To date, most solid tumour targets of engineered T cell therapy rely on overexpression in tumour tissue and are relatively non-specific (for example, GD2, interleukin 13 receptor α2 subunit (IL13Rα2), mesothelin and human epidermal growth factor receptor 2 (HER2; also known as ERBB2)). Nonetheless, a wide variety of potential solid tumour targets are under consideration (TABLES 1,2).
Target selection for T cell treatment of glioblastoma illustrates the variety of approaches available. EGFRvIII is a mutant form of EGFR that generates a novel extracellular epitope. Unlike many other solid tumour markers, expression of EGFRvIII seems to be entirely limited to malignant tissue and is found in approximately 30% of cases of glioblastoma. Conversely, IL13Rα2 is also expressed in many cases of glioblastoma (44-100%, depending on methodology) 69, 70 . Despite being present in more cases, IL13Rα2 is expressed on non-neoplastic tissues at either reduced 70, 71 or comparable 69, 72 levels. Engineered T cell therapy targeting either EGFRvIII or Nature Reviews | Cancer Co-stimulatory signal CD28
Co-stimulatory signal 4-1BB
Co-stimulatory signal CD28
Figure 3 | Chimeric antigen receptor design and evolution. Chimeric antigen receptors (CARs) target surface antigens in a major histocompatibility complex (MHC)-independent manner and consist of an extracellular binding domain, hinge domain, transmembrane domain and intracellular signalling domains. The first clinical trials tested CARs that had a binding domain composed of native CD4 that bound to the envelope glycoprotein gp120 expressed by HIV-infected cells 188, 189 , with a single T cell receptor (TCR) signalling domain composed of the CD3ζ chain [190] [191] [192] . CARs with an extracellular domain composed of antibody single-chain variable fragments (scFvs) were first reported by Kuwana 193 and later by Eshhar and colleagues 194, 195 . Second-generation CARs incorporating CD28 as a co-stimulatory domain were first developed by Roberts (US Patent 5,686,281) and reported by Finney 196 , and those incorporating 4-1BB as a co-stimulatory domain were developed and reported by Finney 197, 198 , Imai 199 and then others 200, 201 . CARs incorporating three or four signalling domains, so called 'third-and fourth-generation' CARs, have also been developed and are beginning to be tested in clinical trials 83, 202, 203 . V H , immunoglobulin heavy chain variable domain; V L , immunoglobulin light chain variable domain. IL13Rα2 has shown promise. EGFRvIII-CAR T cells have been shown to control growth of EGFRvIII + human glioblastoma in preclinical models 63, 73 . Phase I and phase I/II trials are now being conducted to determine the safety and efficacy of EGFRvIII-CAR T cells in treating malignant gliomas 74 (TABLE 2) . EGFRvIII-CAR T cells administered intravenously have been reported to cross the blood-brain barrier, infiltrating tumour (examined following resection) and specific target loss was observed 75 . Despite low level non-neoplastic expression of the target, intracranial administration of IL13Rα2-CAR T cells has been shown to be safe and well tolerated in patients with glioblastoma 76 . IL13Rα2-CAR T cell treatment of IL13Rα2 + brain tumours is under investigation in an active phase I clinical trial (TABLE 2) .
Ganglioside GD2, a glycosphingolipid, is expressed on various tissues, both malignant and benign. GD2 is highly expressed on neuroectodermal tumours (for example, neuroblastoma, melanoma and glioma), sarcomas, brain cancer and small-cell lung cancer [77] [78] [79] . Lowlevel expression of GD2 is also found on non-malignant neurons, skin, melanocytes and peripheral nerves 80 . GD2 monoclonal antibodies have shown efficacy in the setting of minimal residual disease, suggesting that enhanced immune-mediated tumour clearance may be effective in treating GD2 + tumours 81, 82 . GD2 monoclonal antibodies have significant adverse effects, including neuropathic pain, potentially owing to targeting of GD2 + peripheral nerves. GD2-CAR T cells can generate an antitumour immune response in preclinical models 83, 84 and in phase I clinical trials treating patients with GD2 + neuroblastoma 85, 86 . These patients were treated with GD2-CAR T cells and some experienced durable remission regardless of disease status at the time of infusion. Importantly, despite low-level GD2 expression on benign tissue, GD2-CAR T cells were well tolerated with no dose-limiting toxicities observed 85, 86 . These studies were carried out with first-generation CAR T cells, and whether toxicity will be acceptable with more potent CAR designs remains to be determined. A phase I clinical trial is investigating GD2-CAR T cells in patients with various GD2 + malignancies (TABLE 1) . Mesothelin is a 40 kDa cell surface glycoprotein expressed on normal pleura, pericardium and peritoneum 87, 88 and overexpressed on various solid tumours, including pancreatic cancer, mesothelioma and subsets of lung, oesophageal, ovarian and breast cancers [89] [90] [91] [92] [93] [94] [95] . The physiological function of mesothelin is unknown; however, some evidence suggests that in malignancy, the molecule is involved in metastasis, making this an attractive therapeutic target 96 . Intrathoracic and extrathoracic human mesothelioma lesions are eradicated by mesothelin-targeted CAR T cells in preclinical models 97, 98 . These findings confirm that mesothelin-specific CAR T cells can traffic to appropriate body compartments and home to the tumour while retaining antitumour Leukocytes are generally collected by leukapheresis (step 1) and lymphocytes can be enriched (step 2) by counterflow centrifugal elutriation 204 or subsets selected according to cellular phenotype (not shown). The enriched lymphocytes are placed in culture and (step 3) stimulated with bead-based artificial antigen presenting cells 205, 206 , and viral vector (step 4) is added 207 . The culture is expanded in a bioreactor for several days (step 5) and then the T cell bulk product (step 6) is washed and concentrated, samples are removed for quality control release testing (step 7) and quality assurance review. The final formulation is cryopreserved (step 8), enabling easy shipment to distant infusion sites, where the final product bag (step 9) is thawed and infused. Manufacturing time is generally 5-10 days, and collection to infusion times can range from 2 to 4 weeks depending on patient clinical status and chemotherapy conditioning regimens.
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Body sites that resist immune infiltration and activation.
Immune activation threshold
The sum of minimum signals necessary for immune cell activation; specifically for T cell activation, effector function and proliferation.
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effector T cell function. The ability to localize while retaining function is essential for solid tumour eradication, in particular when targeting tumours in immune privileged sites or within an immunosuppressive tumour microenvironment. Preliminary data from human clinical trials have shown mesothelin-specific CAR T cells to be well tolerated and potentially effective against ovarian cancer, mesothelioma and pancreatic cancer 99, 100 . Importantly, despite broad, low-level mesothelin expression on benign tissue, on-target, off-tumour toxicities have not been observed to date. However, these studies were carried out with a CAR that comprised a mouse scFv, resulting in limited persistence of the CAR T cells, potentially owing to host rejection of CAR T cells based on xenogeneic epitopes; whether CAR T cells using a fully human scFv would have durable persistence and acceptable toxicity remains to be determined. Numerous phase I studies are being conducted to further demonstrate the safety and efficacy of mesothelin CAR T cells.
HER2 is a transmembrane receptor tyrosine kinase expressed on normal human gastrointestinal, respiratory, urinary tract, skin, breast and placental tissue. HER2 is also overexpressed in various solid tumours 101 . HER2-targeted T cells may overcome these limitations by actively trafficking to and infiltrating tumour microenvironments and triggering in response to low target density.
Millions of women with breast
However, HER2-targeted T cell therapy also serves as an example of the challenge posed by low-level benign tissue target expression. Lethal pulmonary toxicity was observed in a patient with HER2 + colon cancer who was treated with 10 10 HER2-CAR T cells 106 . It is believed that low-level HER2 expression on pulmonary endothelium triggered this response. This type of reaction was not seen with HER2 monoclonal antibody therapy. This not only suggests that HER2-CAR T cells are able to be activated in response to lower levels of target, but also confirms that mono clonal antibody data are insufficient to predict the safety of T cell therapy. Subsequent HER2-CAR T cell trials have proceeded cautiously by using ultra-low doses of cells. In addition, lymphodepletive preconditioning, which removes endo genous competitors for T cell growth factors, was avoided, as that, along with other factors, may have exacerbated adverse effects 107 . Of note, despite these potential limitations, an anti tumour immune response was still detected in patients with HER2
+ sarcoma treated with HER2-CAR T cells 107 . These findings are even more striking when one considers the relatively low expression of HER2 in these sarcomas. Preclinical studies demonstrate that HER2-CAR T cells have efficacy in clearing HER2
+ glioblastoma and medulloblastoma 108, 109 . Alternatively, HER2-CAR T cells may be manufactured from cytomegalo virus (CMV)-specific autologous T cells, producing a bispecific product that will engage CMV + target cells with the TCR or HER2 + target cells with the CAR, of potential benefit when CMV is also expressed in the tumour micro environment. 
Central tolerance
Mechanism for developing lymphocytes in the thymus and bone marrow to be rendered non-reactive to self antigens.
Antibody-dependent, cell-mediated cytotoxicity (ADCC). Lysis of a target cell bound by antibodies, which is mediated by an immune cell binding to the Fc portion of the antibodies.
Conceptual evolution in redirected T cell targeting in solid tumours.
Clinical feedback has enabled reevaluation of some basic tenets of CAR T cell targeting. Whereas previous approaches emphasized efficacy, minimization of off-tumour effects is now the primary driver of target selection when potent CAR T cells are used. CAR T cells are able to respond to minimal target expression, making target specificity particularly important. Off-tumour effects can be lethal and currently limit clinical applications, particularly with regard to solid tumour therapy. Although intracellular tumour markers have been classically excluded as potential targets, recent work forces their reconsideration. CARs, by definition, are designed with affinity to an extracellular ligand. However, human antibodies with affinity for an epitope of Wilms tumour protein 1 (WT1) presented by human leukocyte antigen (HLA) class I histocompatibility antigen, A-2α chain (HLA-A2) have been developed 114, 115 . Further modifications of these antibodies have enhanced antibody-dependent, cell-mediated cytotoxicity (ADCC) 116 . Thus, whereas TCRs had the advantage of recognizing intracellular antigens presented by MHC to T cells, antibodies that can be incorporated into CAR constructs have now been generated. It is likely that antibodies to additional intracellular antigens presented by MHC will be generated in the future. Inclusion of these intracellular markers as potential targets could improve therapeutic specificity and therefore safety; however, the potential for off-target recognition of this class of CAR T cells remains to be tested.
As the repertoire of potential targets expands, better understanding of cancer biology may enable more precise targeting. Cancer stem cells (CSCs), which are subpopulations of tumour cells with 'stem cell-like' properties, have been identified in ovarian cancer 117 , glioblastoma [118] [119] [120] , multiple myeloma 7 and acute myeloid leukaemia 121, 122 , among others. Because these cells have been associated with disease progression and resistance to therapy, it has been hypothesized that targeting this subpopulation may provide more long-term benefit. Several varieties of CAR T cell have been shown to be capable of eliminating putative CSC subpopulations in preclinical models and one clinical trial 16, 109, [123] [124] [125] . Future strategies to target CSC subpopulations may maximize clinical effect while minimizing off-tumour effects.
Finally, new findings force us to rethink what it means for a T cell therapy to be 'specific' for a target. Two-step approaches are being used, wherein T cells are engineered to express a receptor with affinity for a non-specific molecule and this molecule is then fused to a targetable agent with high affinity for the tumour. For example, Kim et al. 126 (FIG. 5a) . By modifying the tumour stroma, TRUCKs have the ability to enhance tumour infiltration by endogenous immune cells 128 . Finally, despite a great deal of effort to define engineered T cell specificity ex vivo, the specificity of these cells may evolve upon their in vivo stimulation by exposure to tumour cells. After EGFRvIII + tumour cell clearance by EGFRvIII-CAR T cells, mice have been shown to be resistant to subsequent EGFRvIII − tumour challenge 73 . This demonstrates that engineered T cells have the ability to generate immunity to non-target tumour antigens after in vivo antitumour immune response 73, 74 . Together, these findings serve as a reminder that an engineered T cell antitumour response is a dynamic process that relies on both cell design and host factors. (FIG. 3) . Both retroviral and lentiviral vectors are able to deliver moderate-sized payloads, which integrate into host genomes and consistently express the construct. Lentiviral vectors are preferred to retroviral vectors as they may integrate in non-dividing human primary cells and confer a decreased risk of insertional oncogenesis, at least as observed in haematopoietic stem cells [131] [132] [133] [134] [135] . Of note, to date, no lentivirus-transduced engineered T cell products have been reported to demonstrate insertional mutagenesis despite hundreds of patients being treated.
Building smarter redirected T cells
DNA transposons have been used to efficiently insert gene cassettes into the host genomic DNA 130, 136, 137 . Transposon-based systems, such as the Sleeping Beauty (SB) transposon system, have been developed to successfully produce engineered T cells of suitable quality for clinical investigations 138, 139 . The safety and efficacy of transposon-engineered CART19 cells are currently under investigation 140 (NCT00968760). Alternative approaches, such as the PiggyBac transposon system, have also been used to generate several types of engineered T cell (for example, CART19 cells 141 and Epstein-Barr virus (EBV)-specific HER2-CAR T cells 142 ). With viral and non-viral methods of integration, a theoretical risk of insertional oncogenesis remains.
Along with advances in electroporation techniques, the efficiency of non-integrating, non-viral methods of gene modification are showing promise as an alternative or complement to viral vector-based methods. Electroporation also enables provision of non-integrating constructs, such as mRNA, which eliminates the risk of -12) ). Targeted by CAR specificity, localized production of pro-inflammatory cytokines recruits endogenous immune cells to tumour sites and may potentiate an antitumour response. b | Universal, allogeneic CAR T cells are engineered to no longer express endogenous T cell receptor (TCR) and/or major histocompatibility complex (MHC) molecules, thereby preventing graft-versus-host disease (GVHD) or rejection, respectively. c | Self-driving CARs co-express a CAR and a chemokine receptor, which binds to a tumour ligand (for example, C-C motif chemokine receptor 2 (CCR2)-C-C motif chemokine ligand 2 (CCL2)), thereby enhancing tumour homing. d | CAR T cells engineered to be resistant to immunosuppression (armoured CARs) may be genetically modified to no longer express various immune checkpoint molecules (for example, cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or programmed cell death protein 1 (PD1)), with an immune checkpoint switch receptor, or may be administered with a monoclonal antibody that blocks immune checkpoint signalling. e | A self-destruct CAR may be designed using RNA delivered by electroporation to encode the CAR 98, 143 . Alternatively, inducible apoptosis of the T cell (right part of panel g) may be achieved based on ganciclovir binding to thymidine kinase in gene-modified lymphocytes 208 or the more recently described system of activation of human caspase 9 by a small-molecule dimerizer 25, 209 . f | A conditional CAR T cell is by default unresponsive, or switched 'off', until the addition of a small molecule to complete the circuit, enabling full transduction of both signal 1 and signal 2, thereby activating the CAR T cell 126, 169 . Alternatively, T cells may be engineered to express an adaptor-specific receptor with affinity for subsequently administered secondary antibodies directed at target antigen 127 . g | Marked CAR T cells express a CAR plus a tumour epitope to which an existing monoclonal antibody agent binds. In the setting of intolerable adverse effects, administration of the monoclonal antibody clears the CAR T cells and alleviates symptoms with no additional off-tumour effects. h | A tandem CAR (TanCAR) T cell expresses a single CAR consisting of two linked single-chain variable fragments (scFvs) that have different affinities fused to intracellular co-stimulatory domain(s) and a CD3ζ domain. TanCAR T cell activation is achieved only when target cells co-express both targets. i | A dual CAR T cell expresses two separate CARs with different ligand binding targets; one CAR includes only the CD3ζ domain and the other CAR includes only the co-stimulatory domain(s). Dual CAR T cell activation requires co-expression of both targets on the tumour. j | A safety CAR (sCAR) consists of an extracellular scFv fused to an intracellular inhibitory domain (for example, CTLA4 or PD1). sCAR T cells co-expressing a standard CAR become activated only when encountering target cells that possess the standard CAR target but lack the sCAR target.
Graft-versus-host disease (GVHD). Immune reaction of a donor graft containing immune cells against the recipient host that is a by-product of a mismatch in human leukocyte antigens (HLAs). GVHD is a major cause of morbidity following allogeneic haematopoietic stem cell transplantation.
Allogeneic
Genetically distinct but from the same species.
insertional oncogenesis. For these reasons, electroporation of engineered T cells is an emerging strategy for gene modification and interrogation of new tumour targets. As opposed to electroporation of DNA, electroporated mRNA does not require genomic integration for construct expression. Whereas integrated constructs have been observed for more than a decade after transfer of modified cells 17 , electroporated mRNA rapidly degrades and is associated with transient expression 98, 143 . In clinical application, transient expression of a construct may require repeated doses of adoptively transferred cells to achieve adequate effector function and may limit differentiation into a memory phenotype 98, 144 . In humans, RNA-modified mesothelin-CAR T cells have been shown to be safe; however, repeated doses may be problematic if the engineered cells are themselves immunogenic owing to expression of non-self molecules such as scFv, if xenogeneic in origin. Although preliminary evidence suggests that these cells are effective at targeting mesothelin-positive tumours 99 , one case of anaphylaxis has been described in the setting of infusions that were separated by 49 days 145 . Numerous active clinical trials are using mRNA-modified engineered T cells to target malignancy (TABLES 1,2).
Gene editing is one of the most exciting recent developments in the modernization of redirected T cell manu facturing. The overarching term gene editing refers to various techniques that confer particular advantages or disadvantages depending on application. What they share, however, is the ability to efficiently knock out and/or knock in genetic elements. Protein-based (zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs)) and RNA-based (CRISPRCas9) techniques are all, to varying degrees, effective at specific gene disruption or insertion. To produce engineered T cells resistant to tumour-mediated suppression, gene editing may be used to knock out inhibitory receptors and/or knock in an array of function-enhancing molecules.
Efficient gene editing of primary human T cells has been demonstrated using ZFNs, TALENs and CRISPR-Cas9 (REFS 146-151) . Furthermore, the safety of gene-edited T cells in humans was demonstrated by the adoptive transfer of autologous T cells in which C-C motif chemokine receptor 5 (CCR5) was knocked out by ZFNs 151 . The manufacture of gene-edited human CAR T cells has been shown to be feasible with the production of TALEN or CRISPR-Cas9 gene-edited CAR T cells 148, 149 (FIG. 5b) . A preliminary description of the first use of gene-edited CAR T cells in humans was recently reported in an infant with CD19 + ALL for whom autologous CAR T cells were unable to be produced 148 . Instead, engineered CAR T cells were produced from an unrelated donor by deleting the endogenous TCR to prevent graftversus-host disease (GVHD). In addition, CD52, a lymphocyte marker present on the patient's malignant B cells, was deleted from the CAR T cells, enabling treatment with monoclonal antibody against CD52 to eliminate recipient lymphocytes while sparing the infused CD52 -CAR T cells. The patient was heavily preconditioned with chemotherapy to delay donor CAR T cell rejection and thereby enhance CAR T cell persistence. The administration of donor-derived, gene-edited T cells has the potential to revolutionize the current manufacturing paradigm; a single donor could provide starting material to manufacture products for numerous recipients. Although promising, this exciting step forward will require further investigation in more patients to demonstrate the role of allogeneic CAR T cells in tumour control. Safe and effective use of allogeneic CAR T cells may require additional editing of endogenous molecules such as HLA 149, 152 .
Enhancing trafficking. Engineered T cell localization at target sites is crucial for clinical efficacy, particularly when targeting solid tumours 153 . Route of administration and effective trafficking to the tumour site each play an important part in granting T cell access to target tissue. Although T cells can migrate to nearly all body compartments, including immune privileged sites 63, 100 , accumulation of engineered T cells may be enhanced by local administration. In several preclinical solid tumour models, local administration of CAR T cells demonstrated superior accumulation at tumour sites and superior control of tumour growth compared with systemic administration 97, 138, 154 . Notably, in an orthotopic mouse model, intrapleurally injected mesothelin-CAR T cells outperformed systemically administered cells in clearance of intrathoracic and extrathoracic meso thelioma lesions 97 . The superior extrathoracic tumour clearance suggests that early exposure of engineered T cells to tumour immediately after transfer may enhance the activation of CAR T cells via early antigen exposure and may therefore improve their ability to mediate an antitumour response. Furthermore, engineered T cells can be modified to enhance trafficking (FIG. 5c) . Chemokine receptor-ligand interactions have an important role in mediating endogenous immune cell trafficking. In fact, the efficacy of conventional chemotherapeutics is linked to the upregulation of chemokine ligands on tumour cells that is mediated by these drugs 155 . CAR T cells may be engineered to express chemokine receptors to enhance trafficking into tumour tissue and homing to tumour cells. For example, co-expression of the chemo kine receptor CCR2b in CAR T cells targeting either GD2 or meso thelin has been shown to enhance tumour infiltration and antitumour effects in animal models 156, 157 .
Avoiding tumour suppression and escape. Malignancy may be refractory to engineered T cell therapy owing to immune escape or immunosuppression in the tumour microenvironment. Various CD19 mutations and alternative splicing have been associated with the development of CART19-resistant ALL 19 . In this setting multivalent targeting may prevent single-agent resistance. The combination of CD123-and CD19-targeted CAR T cells prevents the outgrowth of CD19 -escape mutants in preclinical models 158 . The tumour microenvironment may also directly inhibit a potential antitumour immune response. By definition, the existence of a tumour is dependent on some degree of evasion or inhibition of endogenous immune control. Inhibition
Immune checkpoints
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Primary signal
The antigen-specific signal delivered to a T cell through the T cell receptor, which is complemented by co-stimulatory signals to achieve full-function T cell activation and effector function.
is achieved through various mechanisms, including cell-cell signalling and release of soluble cytokines. Importantly, like the endogenous immune system, adoptively transferred T cells are also susceptible to tumour-mediated immunosuppression 159 . Furthermore, chronic T cell activation induces upregulation of inhibitory ligands on the activated T cells, perhaps contributing to T cell exhaustion 160 . Various methods can be used to engineer T cells to be intrinsically resistant to tumour immunosuppression (FIG. 5d) . The expression of a dominant-negative transforming growth factor-β (TGFβ) receptor type II confers T cell resistance to this tumour-produced, suppressive cytokine 161 . Others have transduced tumour-specific T cells with hybrid receptors comprising an IL-4 exodomain and an IL-7 endo domain 162 . Tumour-generated IL-4, a suppressive cytokine, produces an activating signal in these engineered T cells. The addition of programmed cell death protein 1 (PD1; also known as PDCD1) monoclonal antibody has been shown to enhance the function of CAR T cells in preclinical models, suggesting that, like endogenous immune cells, engineered T cells are subject to tumour immune suppression through immune checkpoints and would become more effective if disinhibited in this way 163 . Many groups are now attempting to generate CAR T cells resistant to PD1-PD1 ligand 1 (PDL1) or cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-CD80/CD86 signalling 149, 164 . Future T cell therapies are likely to incorporate multiple forms of immune checkpoint blockade to further enhance efficacy.
Improving safety: Boolean logic gates. While treatmentassociated mortality is far below that seen with conventional treatments for relapsed or refractory cancers, serious adverse events have been observed following infusions of engineered T cells. Excessive and rapid tumour clearance has been associated with serious and occasionally fatal CRS. On-target, off-tumour activation of engineered T cells by a very low level of target on non-malignant tissue has been associated with doselimiting toxicities 165 and death in some cases 106, 124 . Finally, unexpected and fatal cross-reactivity seen with engineered TCR T cells demonstrates the current limitations of in vitro screening for cross-reactivity 166, 167 . Molecular 'switches' enable greater control over the performance of engineered T cells in vivo and may improve safety. Cells may be engineered to express prodeath signals that can be induced with an exogenous element (off switch, see FIG. 5e ). Examples of off switches or 'suicide genes' include Herpes simplex virus thymidine kinase (HSV-TK), which can be induced by treatment with ganciclovir, and inducible human caspase 9 (iCasp9), which can be induced by intravenous administration of FK506 binding protein (FK506BP). Deletion of CAR T cells in animal models has been achieved using both HSV-TK-ganciclovir 168 or iCasp9-FK506BP systems 169 . Alternatively, T cells may be engineered to conditionally activate only in the presence of an exogenous molecule, withdrawal of which terminates signalling (on switch) (FIG. 5f) . On switches are currently under development as this technology is less mature. On switches may prove safer than off switches, as the default is no signalling. In addition, removal of the exogenous activator molecule does not necessarily lead to death of the engineered T cell. One can envision repeated dosing of the activator molecule, which can be tailored to the patient's tolerance of the treatment. The feasibility of producing CAR T cells with small-molecule-dependent signalling has been established in preclinical models 170, 171 . In this system, the small-molecule-controlled switch redirects activity of the orthogonal receptor through the selective formation of immunological synapses in a temporally controlled manner. Furthermore, this system is readily adaptable to different antigen targets. Another type of flexible receptor targeting system has recently been described by Lim and colleagues 172 . This system, which is based on synthetic NOTCH receptors, enables conditional expression of a targeting receptor upon engagement with a tissue-specific ligand.
Engineered T cells may be marked with unique cell surface molecules to which approved therapeutic mono clonal antibodies bind (FIG. 5 g ). If this epitope is also expressed on tumour cells, treatment with these monoclonal antibodies could eliminate CAR T cellmediated adverse effects while simultaneously treating the tumour. A fusion of CD34 and CD20 epitopes (RQR8) 148, 173 and a truncated form of human EGFR polypeptide 174 have separately been expressed in CAR T cells. In the setting of intolerable adverse effects, these CAR T cells would be susceptible to elimination by rituximab (mono clonal CD20 antibody) or cetuximab (monoclonal EGFR antibody), respectively. Given the availability of such a wide array of inducible and specific methods of CAR T cell elimination, it is likely that more clinical trials will include such constructs in the future 25, 169, 173, 174 . Deletion of CAR T cells may limit adverse effects, but will also terminate the antitumour clinical effect. Off-tumour toxicity can also be prevented by designing CAR T cells with enhanced specificity. To achieve this, CAR T cells have been designed to activate only in response to a particular combination of targets. For example, bispecific CARs have been generated such that the extracellular portion of the CAR contains two linked scFvs with different specificities (FIG. 5 h) . T cells expressing these tandem CARs (TanCAR) are activated only in the presence of both targets; a target cell positive for a single antigen is insufficient to trigger T cell activation and cell killing. TanCARs against HER2 + CD19 and HER2 + IL13Rα2 have been developed 175, 176 . An alternative to this method is to combine one CAR that transmits only primary signal with a second CAR with distinct tumour antigen specificity that transmits only co-stimulation (FIG. 5i) . In this approach, a single T cell expressing a CD3ζ-only CAR against the first target and a costimulatory domain-only CAR against a second target will become fully activated only in the presence of both targets. Such dual CARs against mesothelin plus FRα and HER2 plus mucin 1 (MUC1) have been shown to generate specific target cytotoxicity against dually expressed targets 177, 178 . Lastly, extracellular scFv fused to inhibitory signalling domains can specifically inhibit CAR T cell activation (FIG. 5j) . These inhibitory signals enable protection of cells with a particular immuno phenotype from CAR T cell killing 179 . Incorporation of all activation and inhibitory signals creates a complex computational algorithm for engineered TCR targeting and decision-making. Importantly, this has enabled reconsideration of targets previously thought to be undesirable owing to off-tumour toxicities. Furthermore, many of the same types of receptor design shown in FIG. 5 may be applied to the next generations of engineered TCRs to improve targeting and control. For example, a selfdestruct or conditional switch may be inserted, along with the engineered TCR. A switch receptor, or armoured TCR, may be created by inserting a decoy receptor that binds to PDL1 on tumours, but provides an accessory signal to augment engineered TCR signalling 164, 180 . These new molecular systems embedded in a cellular drug will soon enable highly specific immunophenotypes to be targeted, off-tumour effects to be minimized and safety to be enhanced in the clinic.
The future of cancer immunotherapy
The advent of kinase-targeted drug therapies and checkpoint blockade antibodies has increased survival in some patients with cancer. In the previous decade, patients with myeloma had an average survival of 2-3 years, and with the advent of improved therapies it is now 7-8 years, and still increasing 181, 182, 148, 149 . Although CLL has remained incurable with standard treatments 151, 183 , the advent of effective targeted therapies such as ibrutinib and idelalisib has significantly extended survival 152, 184 . Immune checkpoint therapies are a new class of cancer immunotherapy that constitutes a major advance in cancer treatment in the past decade, with reproducible benefit observed in 20-30% of patients with various previously incurable cancers 160 . However, there are serious adverse effects and sizeable costs associated with recurrent administration, and most patients do not currently benefit from these therapies. Thus, these therapies, which may require long-term maintenance dosing, present a considerable economic burden for patients and the economy.
In contrast, adoptive cell transfer therapy with engineered T cells has two characteristics that may complement the limitations of kinase-targeted and immune checkpoint therapies. First, engineered T cells require only one treatment for durable benefit 185 . Second, nearly all patients (>90%) with ALL respond to CAR T cells 8, 10 , a response rate not previously observed with other forms of cancer therapy.
Although not yet tested clinically, preclinical models reveal a potent enhancement of antitumour efficacy with the combination of CAR T cells and immune checkpoint blockade 186 (NCT02650999). It is possible that the combination of these therapies could result in the long-term survival and eventual cure of several cancers after only a few treatments 187 . Even today, with early-generation manufacturing, the production and delivery of a one-time treatment delivering durable benefit is disruptive to health care financing and reimbursement models. The expanded availability of redirected T cell therapeutics in cancers beyond haematological malignancies is dependent on the development of automated cell engineering and potentially on the development of universal sources of allogeneic T cells.
